Amanat Acquisition Corp. (AMAN) — Form 8-K Summary
Reporting event: October 25, 2026; filed October 26, 2026. This is a transaction announcement, not a periodic financial report. The filing reports no operating results or financial statements for AMAN or Corxel.
Business context and proposed transaction
AMAN, a Cayman Islands SPAC, entered into a business combination agreement with Corxel Pharmaceuticals, Inc. and its sole stockholder, Corxel Pharmaceuticals Limited. The parties expect to close in the first half of 2027, subject to shareholder and stockholder approvals, regulatory clearance, listing approval, and other closing conditions.
Before closing, AMAN is to domesticate as a Delaware corporation. Merger Sub will merge with Corxel, followed by a second merger into another AMAN subsidiary. The post-closing company is referred to as “New Corxel”; its final name is to be mutually agreed. Corxel shares are to convert into New Corxel shares at an exchange ratio based on an implied Corxel equity value of $200 million. Some consideration may instead be issued as pre-funded warrants. The filing does not provide the final exchange ratio or a complete pro forma ownership breakdown.
Transaction financing and key financial terms
- PIPE: Investors committed to purchase New Corxel shares and/or pre-funded warrants for aggregate commitments of $300 million, subject to conditions and contractual reduction mechanisms. Investors may reduce commitments one-for-one by acquiring and retaining AMAN shares before the shareholder meeting.
- Minimum cash condition: Corxel’s closing condition requires at least $200 million from trust-account cash after redemptions, PIPE proceeds, and eligible additional company cash; the amount of additional cash counted is capped at $75 million.
- Redemptions and balance-sheet condition: AMAN Class A holders may redeem for their pro rata share of trust-account funds. After the business combination, PIPE and redemptions, AMAN must have at least $5,000,001 of net tangible assets immediately after the effective time.
- Warrants and dilution: BCA pre-funded warrants, if issued, have a $0.0001 exercise price, no stated expiration before full exercise, and beneficial-ownership exercise limits of 9.99% (or 4.99% if elected). Equity incentive and employee stock purchase plan share-reserve percentages remain to be agreed; the plans provide for potential future share-pool increases.
- Trust balance threshold for board representation: If more than $25 million remains in AMAN’s trust after redemptions, AMAN will have a New Corxel director, intended to be Rakhi Kumar.
Financial performance and comparison
The filing provides no revenue, profit or loss, cash-flow, margin, debt, or liquidity figures for either company, and no comparable prior-period metrics. It therefore does not permit an assessment of historical financial performance or changes versus a prior period. The investor presentation is referenced as an exhibit, but its contents are not included in the supplied filing text.
Outlook, risks, and unusual terms
- The expected closing date and transaction benefits are forward-looking and depend on satisfaction of closing conditions, including HSR waiting-period clearance, an effective Form S-4/proxy statement, shareholder approvals, and Nasdaq listing approval.
- Corxel must identify and publicly announce a CEO and New Corxel board for the period after closing. The New Corxel board’s size and composition are to be determined by Corxel, subject to the stated provisions.
- The filing identifies risks related to Corxel’s clinical and regulatory development, including CX11 and CX12; financing needs; competition; supply, hiring, and commercialization; and the timing and outcome of clinical trials and regulatory approvals. It also cites redemption levels, regulatory approvals in the U.S., China and other jurisdictions, and the possibility that the transaction will not close.
- Specified termination fees include $10 million for an adverse recommendation change; for a qualifying superior offer, the greater of $10 million and 1% of upfront consideration, capped at $50 million; and reimbursement of AMAN’s documented third-party costs up to $3 million for specified regulatory prohibitions. The agreement limits recovery to one termination fee in applicable circumstances.
- Parent may distribute some or all transaction consideration to its shareholders. Sponsor and Parent lock-ups generally run for six months after closing, subject to permitted transfers and related joinder requirements.
Important facts for investors to verify
- Review the Form S-4/proxy statement for the final exchange ratio, fully diluted ownership and dilution from warrants, options, and equity plans.
- Confirm PIPE funding at closing, including any investor reductions, and the trust balance after redemptions against the $200 million minimum cash condition.
- Assess the companies’ financial statements, cash runway, debt and liabilities, and the proposed use of transaction proceeds; these are not stated in the supplied filing text.
- Review Corxel’s clinical, regulatory, and commercial evidence for CX11, CX12, and other programs, including timelines, costs, and financing requirements.
- Track required approvals, HSR clearance, Nasdaq listing, final governance and leadership arrangements, and the transaction’s expected first-half 2027 closing timetable.